ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02372227
Recruitment Status : Terminated
First Posted : February 26, 2015
Last Update Posted : January 30, 2017
Sponsor:
Information provided by (Responsible Party):
Verastem, Inc.

Brief Summary:
The purpose of this study is to evaluate rising dose levels of VS-5584 administered in combination with a fixed dose of VS-6063 in subjects with relapsed malignant mesothelioma to determine a recommended Phase 2 dose (RP2D) for further development of this combination in this indication.

Condition or disease Intervention/treatment Phase
Relapsed Malignant Mesothelioma Drug: VS-5584 and VS-6063 Phase 1

Detailed Description:

This study is comprised of 2 sequential parts: Part 1 (Dose Escalation of VS-5584) and Part 2 (Expansion). Up to 56 evaluable subjects (i.e., subjects who complete at least 1 cycle [21 days] of therapy) will be enrolled, assuming that:

  • Up to 6 dose levels of VS-5584 are studied in Part 1 (Dose Escalation of VS-5584) in combination with a fixed dose of VS-6063 at 400 mg twice daily (BID) with a maximum of 6 subjects enrolled per VS-5584 dose level, for a total of up to 36 subjects (exclusive of replacement subjects).
  • Up to an additional 20 evaluable subjects may be enrolled in Part 2, the expansion portion of the study. Subjects will be treated with VS-5584 at the RP2D and schedule determined in the dose escalation portion of the study in combination with a fixed dose of VS-6063.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 21 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Dose Escalation Study of VS-5584, a Dual PI3K/mTOR Inhibitor, Administered With a Fixed Dose of VS-6063, a Focal Adhesion Kinase Inhibitor, in Subjects With Relapsed Malignant Mesothelioma
Study Start Date : January 2015
Actual Primary Completion Date : October 2015
Actual Study Completion Date : October 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Mesothelioma

Arm Intervention/treatment
Experimental: VS-5584 and VS-6063 Drug: VS-5584 and VS-6063
Starting dose of VS-5584 will be 20mg taken once daily, 3x/week of each 21 day cycle. All subjects will also receive 2x/day treatment with 400mg VS-6063 in 21 day cycles. Number of Cycles: until progression or unacceptable toxicity develops.




Primary Outcome Measures :
  1. Incidence of dose-limiting toxicities (DLTs) [ Time Frame: 6 months ]
    Dose Escalation Phase: Frequency of DLTs at each dose level associated with administration of VS-5584 and VS-6063 in a 21 day cycle

  2. Safety and tolerability of the combination of VS-5584 and VS-6063 [ Time Frame: 16 months ]
    Dose Escalation Phase and Expansion Phase: A composite by dose level to include incidence of AEs, SAEs (overall and severity), laboratory abnormalities, ECGs, vital signs, Karnofsky Performance Status, dose interruptions and dose reductions as a measure of safety and tolerability


Secondary Outcome Measures :
  1. Pharmacokinetics of VS-5584 & VS-6063 maximum observed plasma concentration (Cmax) [ Time Frame: 0-48 hours per patient ]
  2. Pharmacokinetics of VS-5584 & VS-6063 plasma area under the curve from time zero to last quantifiable concentration (AUClast) [ Time Frame: 0-48 hours per patient ]
  3. Pharmacokinetics of VS-5584 & VS-6063 time to reach maximum observed concentration (Tmax) [ Time Frame: 0-48 hours per patient ]
  4. Pharmacokinetics of VS-5584 & VS-6063 area under the curve from time zero to extrapolated infinite time (AUCO-inf) [ Time Frame: 0-48 hours per patient ]
  5. Pharmacokinetics of VS-5584 & VS-6063 apparent oral clearance (CL/F) [ Time Frame: 0-48 hours per patient ]
  6. Pharmacokinetics of VS-5584 & VS-6063 apparent volume of distribution (Vz/F) [ Time Frame: 0-48 hours per patient ]
  7. Pharmacokinetics of VS-5584 & VS-6063 trough plasma concentration [ Time Frame: 0-48 hours per patient ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histopathologically-confirmed diagnosis of malignant mesothelioma (pleural or peritoneal). Must have disease that has relapsed following at least one prior line of chemotherapy.
  2. Must have received at least 3 cycles of first-line chemotherapy.
  3. Evaluable or measurable disease as assessed by Response Evaluation Criteria in Solid Tumors (RECIST).
  4. Must have archival tumor tissue available for biomarker analysis. A study-specific tumor core biopsy, pleural effusion or ascites sample must be obtained prior to treatment if archival tissue is not available.
  5. Performance status according to the Karnofsky Performance Scale ≥70%.
  6. Fasting blood glucose of ≤ 140 mg/dL (7.8 mmol/L).
  7. Adequate renal function (creatinine ≤ 1.5x upper limit of normal [ULN]) and/or glomerular filtration rate (GFR) of ≥50 mL/min.
  8. Adequate hepatic function (total bilirubin ≤ 1.5x ULN; AST and ALT ≤ 3x ULN).
  9. Adequate bone marrow function (hemoglobin ≥9.0 g/dL; platelets ≥100 x10^9 cells/L; absolute neutrophil count ≥1.5x10^9 cells/L) without the use of hematopoietic growth factors.

Exclusion Criteria:

  1. Have had a previous extra pleural pneumonectomy (EPP).
  2. Gastrointestinal condition which could interfere with the swallowing or absorption of study drug.
  3. Uncontrolled or severe concurrent medical condition (including uncontrolled brain metastases).
  4. Known history of stroke or cerebrovascular accident within 6 months prior to the first dose of study drug.
  5. Any evidence of serious active infection.
  6. Undergoing active treatment for a secondary malignancy.
  7. Cancer-directed therapy (chemotherapy, radiotherapy) within 21 days of the first dose of study drug or 5 half-lives, whichever is shorter.
  8. Major surgery within 28 days prior to the first dose of study drug.
  9. Acute or chronic pancreatitis.
  10. Diabetes mellitus requiring insulin treatment or subjects with a hemoglobin A1C (HbA1C) >7%.
  11. History or evidence of cardiac risk.
  12. Known history of malignant hypertension.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02372227


Locations
United States, Illinois
The University of Chicago Medical Center
Chicago, Illinois, United States, 60637
United States, New York
Memorial Sloane Kettering Cancer Center
New York, New York, United States, 10065
United Kingdom
University of Leicester
Leicester, United Kingdom
The Institute of Cancer Research
Sutton Surrey, United Kingdom
Sponsors and Collaborators
Verastem, Inc.
Investigators
Study Chair: Hagop Youssoufian Verastem, Inc.

Responsible Party: Verastem, Inc.
ClinicalTrials.gov Identifier: NCT02372227     History of Changes
Other Study ID Numbers: VS-6063-104
First Posted: February 26, 2015    Key Record Dates
Last Update Posted: January 30, 2017
Last Verified: January 2017

Additional relevant MeSH terms:
Mesothelioma
Lung Neoplasms
Adenoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Mesothelial
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases